Michael E. Prevoznik - 04 Mar 2026 Form 4 Insider Report for QUEST DIAGNOSTICS INC (DGX)

Reporting relationship: SVP & General Counsel
Issuer ticker: DGX
Reported as of: 04 Mar 2026
Net transaction value: -$799,682
SEC form: 4
Accepted by SEC: 06 Mar 2026, 16:44:30 UTC
Prior SEC filing: 04 Mar 2026
Source filing: View source filing
Reporting owner signature: Sean D. Mersten, Attorney in Fact for Michael E. Prevoznik

Key filing fact

Michael E. Prevoznik filed Form 4 for QUEST DIAGNOSTICS INC (DGX) on 06 Mar 2026.

Key facts

This page summarizes Michael E. Prevoznik's Form 4 filing for QUEST DIAGNOSTICS INC (DGX).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 06 Mar 2026, 16:44.

Change

Previous filing in this sequence was filed on 04 Mar 2026.
Current net transaction value: -$799,682.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001222679 Primary reporting owner

PREVOZNIK MICHAEL E

Relationship: SVP & General Counsel
Address: 500 PLAZA DRIVE, SECAUCUS
Signature: Sean D. Mersten, Attorney in Fact for Michael E. Prevoznik
Signature date: 06 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DGX transaction

Common Stock

Award

Transaction value
Shares: +7,232
Change %: +19%
Price: $204.86^*
Shares after: 44,789
Date: 04 Mar 2026
Ownership: Direct
Footnotes: F1

DGX transaction

Common Stock

Tax liability

Transaction value
Shares: -3,354
Change %: -7.5%
Price: $204.86^*
Shares after: 41,435
Date: 04 Mar 2026
Ownership: Direct
Footnotes: F2

DGX transaction

Common Stock

Sale

Transaction value: $799,682
Shares: -3,878
Change %: -9.4%
Price: $206.21
Shares after: 37,557
Date: 05 Mar 2026
Ownership: Direct
Footnotes: F3

DGX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 5,737
Date: 04 Mar 2026
Ownership: 401(k)/SDCP
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Stock issued by Quest Diagnostics Incorporated in settlement of a performance stock award approved in accordance with the requirements of Rule 16b-3(d).

Footnote F2

Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance stock award.

Footnote F3

This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

Footnote F4

These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.